China's Neurophth raises nearly $100m as it nears commercialisation of lead candidate

China’s Neurophth Therapeutics, which develops in-vivo gene therapies for ophthalmic diseases, announced on Wednesday the completion of its Series C+ funding round at almost 700 million yuan ($97.7 million).